Phan T M, Foster C S, Boruchoff S A, Zagachin L M, Colvin R B
Hilles Immunology Laboratory, Massachusetts Eye and Ear Infirmary, Boston.
Am J Ophthalmol. 1987 Nov 15;104(5):494-501. doi: 10.1016/s0002-9394(14)74107-8.
Six patients with persistent corneal epithelial defects that failed to improve with standard therapy were treated with topical fibronectin in a phase I uncontrolled trial. Fibronectin was purified from autologous plasma by affinity chromatography and administered topically, 0.5 mg/ml five times a day, for three weeks. Complete reepithelialization was achieved in five patients: three healed three to 17 days after initiation of treatment while two healed one to two weeks after discontinuation of topical fibronectin. No side effects were observed. Over a follow-up period of three to 18 months, two recurrences were noted.
